Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06201416 · ClinicalTrials.gov registry record · Phase 1
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
A Phase 1 study of Rheumatoid Arthritis, sponsored by Sonoma Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 8
- Study locations
NCT06201416: Recruiting Phase 1 study of Rheumatoid Arthritis, sponsored by Sonoma Biotherapeutics.
NCT06201416 is a Phase 1 study of Rheumatoid Arthritis that is actively recruiting participants, run by Sonoma Biotherapeutics. The registered enrollment target is 24 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06201416, a Phase 1 study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by Sonoma Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown.
Conditions Studied
Interventions
- BIOLOGICAL SBT777101
Study Locations (8)
Massachusetts
- Tufts University - Boston
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
California
- UCSF Medical Center - San Francisco
- Stanford Medical Center - Stanford
Arizona
- Mayo Clinic - Scottsdale
Colorado
- University of Colorado - Aurora
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What NCT06201416 shows while recruiting
NCT06201416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which SBT777101 is the first listed.
NCT06201416 lists 8 locations in 5 states (Massachusetts, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT06201416 about?
NCT06201416 is a clinical study titled "Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis". This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown.
What is the current status of trial NCT06201416?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-03-06. Estimated completion is 2026-03.
What conditions does trial NCT06201416 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06201416?
The interventions under investigation include: SBT777101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06201416?
This trial is sponsored by Sonoma Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06201416 being conducted?
This trial has 8 study locations across Arizona, California, Colorado, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06201416's enrollment target sits among peer trials
24 173rd of 197 higher than 24 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI